The estimated Net Worth of Cameron Turtle is at least $6.4 Million dollars as of 28 December 2020. Dr Turtle owns over 19,500 units of BridgeBio Pharma Inc stock worth over $897,583 and over the last 5 years he sold BBIO stock worth over $4,883,581. In addition, he makes $621,400 as Chief Strategy Officer at BridgeBio Pharma Inc.
Dr has made over 24 trades of the BridgeBio Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 19,500 units of BBIO stock worth $130,455 on 28 December 2020.
The largest trade he's ever made was exercising 26,294 units of BridgeBio Pharma Inc stock on 15 December 2020 worth over $363,909. On average, Dr trades about 6,934 units every 19 days since 2019. As of 28 December 2020 he still owns at least 32,068 units of BridgeBio Pharma Inc stock.
You can see the complete history of Dr Turtle stock trades at the bottom of the page.
Dr. Cameron Turtle DPHIL, Ph.D. is the Chief Strategy Officer at BridgeBio Pharma Inc.
As the Chief Strategy Officer of BridgeBio Pharma Inc, the total compensation of Dr D at BridgeBio Pharma Inc is $621,400. There are 14 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
Dr D is 31, he's been the Chief Strategy Officer of BridgeBio Pharma Inc since . There are 19 older and 2 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Cameron's mailing address filed with the SEC is 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, and Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: